The use of GH is approved by the US Food and Drug Administration for the treatment of growth failure associated with growth hormone deficiency (GHD), either isolated (IGHD) or part of multiple pituitary hormone deficiency (MPHD), and short stature associated with Turner syndrome (TS), Noonan syndrome (NS), children born small for gestational age (SGA), short stature homeobox (SHOX) gene haploinsufficiency, Prader-Willi syndrome (PWS), chronic kidney disease (CKD), or idiopathic short stature (ISS) [1]. This evidence concerns the gene SHOX and SHOX-related short stature.